Skip to search boxSkip to navigationSkip to main content

Activator of G protein signaling 3: A gatekeeper of cocaine sensitization and drug seeking

  • M. Scott Bowers
    ,
  • Krista McFarland
    ,
  • Russell W. Lake
    ,
  • Yuri K. Peterson
    ,
  • Christopher C. Lapish
    ,
  • Mary Lee Gregory
*Corresponding author for this work
  • Medical University of South Carolina
    ,
  • Louisiana State University Health Sciences Center
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Chronic cocaine administration reduces G protein signaling efficacy. Here, we report that the expression of AGS3, which binds to GiαGDP and inhibits GDP dissociation, was upregulated in the prefrontal cortex (PFC) during late withdrawal from repeated cocaine administration. Increased AGS3 was mimicked in the PFC of drug-naive rats by microinjecting a peptide containing the Giα binding domain (GPR) of AGS3 fused to the cell permeability domain of HIV-Tat. Infusion of Tat-GPR mimicked the phenotype of chronic cocaine-treated rats by manifesting sensitized locomotor behavior and drug seeking and by increasing glutamate transmission in nucleus accumbens. By preventing cocaine withdrawal-induced AGS3 expression with antisense oligonucleotides, signaling through Giα was normalized, and both cocaine-induced relapse to drug seeking and locomotor sensitization were prevented. When antisense oligonucleotide infusion was discontinued, drug seeking and sensitization were restored. It is proposed that AGS3 gates the expression of cocaine-induced plasticity by regulating G protein signaling in the PFC.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 269-281 (13 pages)

Journal (Volume, Issue Number)

Neuron (Volume 42, Issue 2)

Publication milestones

  • Published - 04/22/2004

Publication status

Published - 04/22/2004

ISSN

0896-6273

Publication IDs

  • Scopus: 4043053853
  • PubMed: 15091342

Publication metrics

Metrics

SciVal
citations
192
Fractional count
1
Fractional count
0.13
Fractional count
7
Fractional count
0.88
Fractional count
1
Fractional count
1
SciVal
FWCI
4.36
SciVal
Author count
8
SciVal
Paper percentile
97
SciVal
Top percentile
5
Scopus
citations

PlumX, opens in new tab

Citation count
212
Captures
110

Funding Details

This research was supported in part by United States Public Health Service grants #MH-40817 (P.W.K.), DA-03960 (P.W.K.), DA-12513 (P.W.K.), DA-015369 (P.W.K.), MH-90531 (S.M.L.), and NS-24821 (S.M.L.). S.M.L. is greatly appreciative for this support and that provided by the David R. Bethune/Lederle Laboratories Professorship in Pharmacology and the Research Scholar Award from Yamanouchi Pharmaceutical Company, LTD.
FundersFunding numbers
NINDS
R29NS024821
USPHS
DA-015369, MH-90531, -40817, DA-03960, DA-12513